abstract: Impairment of movement execution in @entity191 could be due to @entity73 and/or of activation. These two factors are hard to separate by measuring response times only. Therefore, in this study response force and event-related EEG potentials were measured continuously during tasks in which subjects had to respond to cued signals. Fifteen @entity1 with @entity191 and 15 healthy subjects were studied during two tasks: (i) the 'clock task', in which the signal's identity was fully precued but its presentation time was uncertain and (ii) the 'validity task' in which the cue did not always predict the response validly. Thus, the clock task required more sustained attention, and the validity task sometimes required fast switching. The @entity1 generally responded slower than control subjects. In the clock task, the response times of both groups changed to the same extent with presentation time, whereas in the validity task the @entity1 were additionally slower than the control group with invalidly cued signals. The @entity1 generally had a weaker response force and a lower rate of force production. In the clock task, both force measures changed with presentation time in the control group only, whereas in the validity task, the two measures increased in both groups to the same extent with invalidly cued signals. The contingent negative variation amplitudes in the @entity1 ' event-related EEG potentials were reduced, reflecting reduced activation of movement preparation, whereas lateralization of the motor cortices (i.e. the lateralized readiness potential) did not differ significantly between groups, reflecting unimpaired response selection. Force and contingent negative variation were generally reduced in the @entity1 showing that their general slowing is at least partially due to impaired activation. Task-specific problems added to the general activation deficit; the lack of modulation of response force by presentation time revealed pronounced deficits of activation in the monotonous clock task. The specific delay of responses with invalidly cued signals, unparalleled by activation measures, might suggest a problem of cognition. The task-specific deficits may reflect a basic dilemma for @entity1 with @entity191 : @entity73 may arise in complex tasks but disorders of activation may become pronounced in more simple, monotonous tasks.

title: Responses to cued signals in XXXX . @entity73 and of activation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['disorders of cognition', 'cognitive problems']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: The objective of the present study was to determine the effects of inhibition of @entity12308 biosynthesis on fertility and embryonic survival in laying @entity1573 . White Leghorn hens were fed for 5 weeks with a control diet alone or a diet supplemented with one of two concentrations (0.03 or 0.06%) of the @entity2453 reductase inhibitors @entity2993 , @entity5753 or @entity3413 . The hens were artificially inseminated once a week and eggs that were not analysed for @entity165 content were incubated. When averaged across dietary groups and expressed as a percentage of all eggs incubated, the incidence of unfertilized eggs was 1.6% (controls), 29.1% ( @entity2993 ), 4.4% ( @entity5753 ) and 7.9% ( @entity3413 ). In contrast, with the exception of lower values for birds fed 0.06% @entity2993 , all groups had comparable hatchabilities of fertilized eggs. Hatchability of all eggs incubated was decreased in both @entity2993 groups compared with the other treatments. However, embryonic mortality of fertilized eggs was unaffected (P > 0.05) by diet. Compared with controls, maximum decreases in egg @entity165 of 46, 22 and 7% were obtained with @entity2993 , @entity5753 and @entity3413 , respectively. Although the overall correlation of egg @entity165 content with hatchability was high (r = 0.82), the hatch rate of eggs containing approximately 105 mg @entity165 ranged from 0 to 67%, indicating that egg @entity165 content was not the only factor influencing embryo survival. This is the first study to indicate that a @entity12308 -derived product or products plays an important role in avian fertility. In addition, this work challenges the contention that virtually all of the @entity165 in @entity1573 egg yolk is essential for embryonic development and survival.

title: Relationship between inhibition of XXXX biosynthesis and reduced fertility in laying hens.

entities_list: @entity12308 :: ('MESH:D008798', 'Chemical') :: ['mevalonate']

entities_list: @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin']

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin']

entities_list: @entity5753 :: ('MESH:D008148', 'Chemical') :: ['lovastatin']

entities_list: @entity1573 :: ('9031', 'Species') :: ['chickens', 'chicken']

entities_list: @entity2453 :: ('MESH:C008047', 'Chemical') :: ['3-hydroxy-3-methylglutaryl-coenzyme A']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity12308 :: (MESH:D008798,Chemical) :: ['mevalonate']


abstract: Automated immunoassay systems should be convenient to handle, flexible and give reliable results. To investigate the extent to which the UniCAP System met the above requirements, compared with the IMMULITE System, we compared the Phadiatop (UniCAP) and AlaTOP (IMMULITE) results of 110 @entity1 with positive clinical diagnoses for inhalant @entity566 . In addition, we compared food screening test results of 103 @entity1 with a clinical positive diagnosis for food, and 110 test results of controls with negative diagnosis for @entity566 . Phadiatop had a sensitivity of 96% and a specificity of 92%. AlaTOP had a sensitivity of 86% and a specificity of 94%. For food screening the results were: 75% sensitivity and 82% specificity for fx5 (UniCAP) and 63% sensitivity and 71% specificity for fp5 (IMMULITE). Furthermore, those samples for which the test results which were not in concordance with the clinical diagnosis were tested with the follow-up panel of the different screening tests. For the AlaTOP follow-up we had to use the DPC microplate System (Milenia), because single allergen testing is not yet possible on the IMMULITE System. With regard to sensitivity, the UniCAP specific inhalant allergen tests and the original Phadiatop results showed closer agreement with each other than did the Milenia specific allergen results with the AlaTOP. The specificity of the single inhalant allergen tests was the same for both systems. For @entity5419 testing the UniCAP System shows closer agreement between the screening and the follow-up results than does the IMMULITE. The hands on time for loading 44 samples was practically the same for both systems, but for the follow-up tests the Milenia System is used next to the IMMULITE. Therefore from a logistical point of view the UniCAP System is more convenient. From these results we conclude that both logistically and clinically UniCAP seems to meet our requirements better than the IMMULITE.

title: The first fully automated @entity566 analyser UniCAP: comparison with IMMULITE for XXXX panel testing.

entities_list: @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergy']

answer: @entity566 :: (MESH:D006967,Disease) :: ['allergy']


abstract: Two germicides, one containing 0.5% @entity1216 and one containing 1% @entity1496 , were tested for efficacy against new intramammary infections (IMI) caused by @entity794 and @entity5967 . The model for the experimental challenge in the trials that were designed to test the efficacy of the two postmilking teat dips was recommended by the National @entity1271 Council. The 0.5% @entity1216 product reduced the number of new IMI caused by Staph. aureus by 73.2% and reduced the number of new IMI caused by Strep. agalactiae by 53.9%. The 1% @entity1496 product reduced the number of new IMI caused by Staph. aureus by 75.6% and reduced the number of new IMI caused by Strep. agalactiae by 53.5%. In both trials, the incidence of clinical @entity1271 was also reduced in dipped quarters compared with control quarters. Use of the two teat dips over the trial periods had no effect on the condition of teat skin or teat ends.

title: Efficacies of teat germicides containing 0.5% @entity1216 and 1% XXXX during experimental challenge with @entity794 and @entity5967 .

entities_list: @entity1216 :: ('MESH:D002710', 'Chemical') :: ['chlorhexidine']

entities_list: @entity5967 :: ('1311', 'Species') :: ['Streptococcus agalactiae']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity1271 :: ('MESH:D008413', 'Disease') :: ['Mastitis', 'mastitis']

answer: @entity1496 :: (MESH:D007455,Chemical) :: ['iodine']


abstract: PURPOSE: The aim of this study was to ascertain recent trends in noninvasive imaging utilization for suspected @entity453 . METHODS: The Medicare Part B databases for 2001 to 2013 were reviewed. Current Procedural Terminology primary codes for radionuclide myocardial perfusion imaging (MPI), @entity1642 ( @entity1642 ), and coronary CT angiography (CCTA) were selected. Physician specialty codes were used to designate providers as radiologists, cardiologists, and all others as a group. Procedure volumes were tabulated, and utilization rates per 1,000 Medicare beneficiaries were calculated over the period of study. RESULTS: Total MPI utilization rates per 1,000 rose rapidly from 63.4 in 2001 to a peak of 88.0 in 2006 but declined every year thereafter, dropping to 61.9 in 2013. @entity1642 rates generally held steady around 12 to 13 from 2001 to 2010 but then began to decline, reaching 10.8 in  2013. Cardiologists predominate in both MPI and @entity1642 . CCTA rates were far lower. They peaked at 2.1 in 2007, but then dropped before  leveling off at 1.07 in both 2012 and 2013. Radiologists and cardiologists have approximately equal roles in this procedure. CONCLUSIONS: Both MPI and @entity1642 seem to be declining in use in recent years. This is likely due to unfavorable reimbursement trends caused by code bundling and resulting in the closure of many private cardiology offices. CCTA use is far lower than the two other types of imaging and has also declined in recent years. This is puzzling, as it is a new and promising procedure that has some advantages over MPI and @entity1642 . In 2013, 58 times as many MPI studies as CCTA studies were performed.

title: Recent Trends in Imaging for Suspected XXXX : What Is the Best Approach?

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity1642 :: ('MESH:D015775', 'Disease') :: ['stress echocardiography', 'SE']

answer: @entity453 :: (MESH:D003324,Disease) :: ['Coronary Artery Disease']


abstract: PURPOSE: Most studies on treatment of prosody in individuals with @entity4653 due to @entity191 are based on intensive treatment of loudness. The present study investigates the effect of intensive treatment of speech rate and intonation on the intelligibility of individuals with @entity4653 due to @entity191 . METHODS: A one group pretest-posttest design was used to compare intelligibility, speech rate, and intonation before and after treatment. @entity1 included eleven Dutch-speaking individuals with predominantly moderate @entity4653 due to @entity191 , who received five one-hour treatment sessions per week during three weeks. Treatment focused on lowering speech rate and magnifying the phrase final intonation contrast between statements and questions. Intelligibility was perceptually assessed using a standardized sentence intelligibility test. Speech rate was automatically assessed during the sentence intelligibility test as well as during a passage reading task and a storytelling task. Intonation was perceptually assessed using a sentence reading task and a sentence repetition task, and also acoustically analyzed in terms of maximum fundamental frequency. RESULTS: After treatment, there was a significant improvement of sentence intelligibility (effect size .83), a significant increase of pause frequency during the passage reading task, a significant improvement of correct listener identification of statements and questions, and a significant increase of the maximum fundamental frequency in the final syllable of questions during both intonation tasks. CONCLUSION: The findings suggest that @entity1 were more intelligible and more able to manipulate pause frequency and statement-question intonation after treatment. However, the relationship between the change in intelligibility on the one hand and the changes in speech rate and intonation on the other hand is not yet fully understood. Results are nuanced in the light of the operated research design. LEARNING OUTCOMES: The reader will be able to: (1) describe the effect of intensive speech rate and intonation treatment on intelligibility of speakers with @entity4653 due to @entity1726 , (2) describe the effect of intensive speech rate treatment on rate manipulation by speakers with @entity4653 due to @entity1726 , and (3) describe the effect of intensive intonation treatment on manipulation of the phrase final intonation contrast between statements and questions by speakers with @entity4653 due to @entity1726 .

title: The effect of intensive speech rate and intonation therapy on intelligibility in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['dysarthria']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: PURPOSE: To determine the safety and outcomes of performing endovascular interventions across pacemaker (PM) lead-related central @entity850 /occlusion. MATERIALS AND METHODS: Clinical and imaging records from April 2002 to August 2010 were reviewed for @entity1 presenting with clinically significant central @entity1211 or central @entity432 with indwelling PM leads and were evaluated to determine if any @entity409 or complications occurred following intervention. Thirteen @entity1 were identified who underwent 14 interventions. Outcomes were assessed based on recurrent clinical symptoms and repeat venograms, and patency was determined with Kaplan-Meier analysis. RESULTS: All procedures were technically successful (100%) with no procedural complications. All @entity1 underwent balloon angioplasty; two @entity1 also underwent stent placement for persistent flow-limiting @entity850 within the superior vena cava. No incidence of PM or @entity409 , @entity281 , or need for PM intervention was identified in any @entity1 at the time of the index procedure and at 30 or 90 days. In the two @entity1 who received stents across PM leads, no manifestations of PM or @entity409 or @entity281 , or need for intervention, were identified at 1 year after stent placement in one @entity1 and at 3 years in the other @entity1 . For eight @entity1 , sufficient follow-up studies were available, with 30-, 60-, and 120-day primary patency rates of 87.5%, 75%, and 50%, respectively. CONCLUSIONS: Endovascular interventions across PM leads resulted in no adverse clinical cardiac or PM sequelae, but with limited primary patency compared with historical outcomes for central venous interventions in the absence of PM leads.

title: Central XXXX associated with pacemaker leads: short-term results of endovascular interventions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['lead dysfunction']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['venous obstruction']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['vein stenosis', 'stenosis']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous stenosis']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous stenosis']


abstract: The present study was conducted to determine the 24, 48, 72, and 96-h median lethal concentration (LC50) of @entity43963 and investigate the antioxidant response and acetylcholinesterase (AChE) activities in liver, gill, and spleen of @entity39729 exposed to 0 (control), 5, and 10 mg/L @entity43963 , at the fixed interval time of 24, 48, 72, and 96 h, respectively. LC50 value was 60.83 mg/L at 24 h, 51.36 mg/L at 48 h, 47.07 mg/L at 72 h and 40.13 mg/L at 96 h, respectively. Dismutase (SOD), catalase (CAT), AChE activities, and @entity1234 ( @entity1865 ) levels in these tissues for the control remained stable over the exposure period. However, for the two tested groups, tissue-, dose-, and time-dependent responses of these parameters were observed in @entity39729 . In general, hepatic SOD and CAT activities were significantly inhibited at 24 h, activated, and increased at 48 h, but again inhibited from 48 to 96 h in fish exposed to the two tested concentrations. Hepatic @entity1865 levels of fish for the two tested concentration peaked at 48 h, significantly higher than the control. Hepatic AChE activity was inhibited at 24 h, peaked at 48 h, and then declined at 72 h for the two tested groups. For gills, the highest SOD and CAT activities for the two tested groups were observed at 48 h, higher than the control. AChE activities for the two tested groups were significantly inhibited at 24 h, but activated at 48 h. At 96 h, AChE activities among the treatments showed no significant differences. Gill @entity1865 levels at 48 h for the tested groups were significantly higher than the control, but showed no significant differences at 24 and 72 h among the treatments. In spleen, SOD and CAT activities at 48 h for the two tested groups were significantly higher than those in the control, but at 96 h the vice versa was true. Spleenic AChE activities and @entity1865 levels for the two tested groups were inhibited at 24 h, activated at 48 h, and then were again inhibited at 72 h. Based on these observations earlier, the results obtained in our study will have important toxicological implications for waterborne @entity43963 pollution and, meantime, provide the basis for the effective risk assessment of @entity43963 in water environment and appropriate safety recommendations for fish.

title: Effects of waterborne @entity43963 exposure on antioxidant responses and acetylcholinesterase activities in XXXX .

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity39729 :: ('267130', 'Species') :: ['S. hasta', 'Synechogobius hasta']

answer: @entity39729 :: (267130,Species) :: ['Synechogobius hasta']


abstract: BACKGROUND: One of the modalities of treatment for @entity0 surgery @entity158 is opioids, and opioids are associated with adverse effects such as @entity1209 (PONV). Intravenous (IV) @entity3303 has been shown to reduce opioid consumption and to improve overall postoperative outcomes in abdominal surgery. In this study, we tested the effect of intraoperative IV @entity3303 infusion on the quality of postoperative recovery after @entity0 surgery. METHODS: Seventy-one @entity1 undergoing @entity0 surgery were randomly assigned to receive either placebo (group P; n = 34) or IV @entity3303 (group L; n = 37, bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/h, stopped 2 hours after the end of surgery) in a prospective double-blind design. Intraoperative and postoperative @entity1286 consumption was calculated. @entity282 scores, PONV, and @entity1295 were assessed at 2, 24, and 48 hours after surgery. Duration of postoperative hospital stay was recorded. RESULTS: Demographics were the same between the groups. There was no statistically significant difference in intraoperative or postoperative @entity1286 consumption (P = 0.188 and P = 0.758) between groups. Overall @entity158 scores either at rest or activity (P = 0.348 and P = 0.810, respectively), PONV (P = 0.350), @entity1295 (P = 0.758), or duration of postoperative hospital stay (P = 0.218) were not statistically different. CONCLUSIONS: Our findings did not show a significant effect of IV @entity3303 during @entity0 surgery on opioid consumption, @entity158 score, PONV, or @entity1295 , indicating that the benefit of this approach does not generalize across all types of surgery.

title: Effect of intravenous @entity3303 on postoperative recovery of XXXX undergoing mastectomy: a double-blind, placebo-controlled randomized trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['Postoperative pain']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['itching and postoperative nausea and vomiting']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: This study aims to present methods and baseline data from the Early versus Late Intervention Trial with @entity53 (ELITE), the only clinical trial designed to specifically test the timing hypothesis of postmenopausal @entity34 ( @entity34 ). The timing hypothesis posits that @entity34 effects depend on the temporal initiation of @entity34 relative to time since menopause. METHODS: ELITE is a randomized, double-blind, placebo-controlled trial with a 2 * 2 factorial design. Six hundred forty-three healthy postmenopausal @entity1 without @entity65 were randomized to oral @entity53 or placebo for up to 6 to 7 years according to time since menopause (<6 or >= 10 y). @entity2998 ( @entity2998 ) and cardiac computed tomography were conducted to determine @entity34 effects on subclinical @entity731 across menopause strata. RESULTS: @entity1 in the early and late postmenopausal strata were well-separated by mean age (55.4 vs 65.4 y) and median time since menopause (3.5 vs 14.3 y). Expected risk factors (age, blood pressure, and body mass index) were associated with @entity2998 at baseline in both strata. In the early postmenopausal group, but not in the late postmenopausal group, we observed significant associations between @entity2998 and factors that may play a role in the responsiveness of @entity731 progression according to timing of @entity34 initiation. These include low-density lipoprotein @entity165 , high-density lipoprotein @entity165 , sex hormone-binding globulin, and serum total @entity53 . CONCLUSIONS: The ELITE randomized controlled trial is timely and unique. Baseline data indicate that ELITE is well-positioned to test the @entity34 timing hypothesis in relation to @entity731 progression and @entity453 .

title: Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with XXXX testing the menopausal hormone timing hypothesis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Participants']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['CIMT', 'Carotid artery intima-media thickness']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['Estradiol', 'estradiol']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['hormone therapy', 'HT']

answer: @entity53 :: (MESH:D004958,Chemical) :: ['Estradiol']


abstract: BACKGROUND: Coagulase-negative staphylococci (CNS) are a common cause of @entity580 . In recent years, an increase in the incidence of @entity3256 -resistant coagulase-negative staphylococci (MRCNS) has led to the severity of the disease. OBJECTIVES: The aim of this study was to isolate and identify MRCNS strains by @entity6101 disk agar diffusion, @entity6101 agar screening, and polymerase chain reaction (PCR) and to evaluate their antibacterial resistance patterns. @entity1 AND METHODS: Totally, 122 CNS isolates were collected from the clinical specimens of four hospitals in Iran. Susceptibility testing was performed by disk agar diffusion against 15 antimicrobial agents. Then, disk agar diffusion, agar screening, and PCR were applied to determine susceptibility to @entity6101 . RESULTS: Out of the 122 isolates, 92 isolates were found to be MRCNS by PCR. The sensitivities and specificities of disk agar diffusion and agar screening were 89.2% and 69% and 93.8% and 96.3%, respectively. Also, 93 CNS isolates were resistant to @entity3256 according to disk agar diffusion. DISCUSSION: Our results indicated that agar screening was superior to @entity6101 disk agar diffusion. A comparison between the antibiotic sensitivity patterns of the MRCNS and the @entity3256 -Susceptible Coagulase-Negative Staphylococci (MSCNS) showed that the MRCNS were predominantly multiple-drug resistant isolates as the simultaneous resistance rate to 4 or more antibiotics in the MRCNS and MSCNS was 93% and 56%, respectively.

title: Detection of XXXX -Resistant Coagulase-Negative Staphylococci and Surveillance of Antibacterial Resistance in a Multi-Center Study from Iran.

entities_list: @entity6101 :: ('MESH:D010068', 'Chemical') :: ['oxacillin']

entities_list: @entity3256 :: ('MESH:D008712', 'Chemical') :: ['Methicillin', 'methicillin']

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infections']

answer: @entity3256 :: (MESH:D008712,Chemical) :: ['Methicillin']


abstract: We wanted to determine whether allogeneic hematopoietic stem cell transplantation (HSCT) may result in long-term survival in @entity1 with solid @entity5 . HSCT was performed in 61 @entity1 with solid @entity5 : metastatic @entity703 (n  =  22), @entity201 (n  =  17), @entity694 (n  =  15), @entity263 (n  =  3), @entity788 (n  =  3), or @entity0 (n  =  1). Liver transplantation was performed for @entity5 debulking in 18 @entity1 . Median age was 56  years (range, 28 to 77). Donors were either HLA-identical siblings (n  =  29) or unrelated (n  =  32). Conditioning was nonmyeloablative (n  =  23), reduced (n  =  36), or myeloablative (n  =  2). Graft failure occurred in 13 @entity1 (21%). The cumulative incidence of @entity2132 ( @entity2132 ) of grades II to IV was 47%, and that of chronic @entity2132 was 32%. Treatment-related mortality was 21%. At 5  years @entity5 -related mortality was 63%. Currently, 6 @entity1 are alive, 2 with @entity1358 , 1 with @entity201 , and 3 with @entity3123 . Eight-year survival was 12%. Risk factors for mortality were nonmyeloablative conditioning (HR, 2.95; P  <  .001), absence of chronic @entity2132 (HR, 3.57; P  <  .001), acute @entity2132 of grades II to IV (HR, 2.90; P  =  .002), and HLA-identical transplant (HR, 5.00; P  =  .03). With none of these risk factors, survival at 6  years was 50% (n  =  6). Long-term survival can be achieved in some @entity1 with solid @entity5 after HSCT.

title: Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'acute graft-versus-host disease']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon carcinoma']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal carcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']


abstract: BACKGROUND: The macrofollicular variant of @entity3557 that is the subject of this study has only recently been characterized. Information about its morphologic spectrum and biologic behavior is limited. METHODS: The authors reviewed 29 examples, including 17 previously reported cases. The clinical and pathologic features of five @entity1 who had the macrofollicular variant of @entity3557 with a @entity2483 were analyzed in detail. The insular component in @entity259 has been associated with @entity146 clinical behavior. RESULTS: The ages of the 5 @entity1 ranged from 31 to 70 years; the mean age was 40 years. Three @entity1 presented with a palpable thyroid nodule and two with a large thyroid mass of long duration. The latter two @entity5 , which metastasized, were the largest (8 and 11 cm) and showed @entity3120 . All five @entity5 were composed predominantly of macrofollicles (>50%) and had a @entity2483 that comprised less than 5% of the @entity5 mass. In most @entity5 , the macrofollicles were lined by cells with large, clear, grooved nuclei, and all five contained areas of conventional follicular variant of @entity3557 . In the two that metastasized, however, the lining of many macrofollicles consisted of cuboidal cells with small, hyperchromatic, follicular-type nuclei. Only the macrofollicular component was identified in the metastatic deposits in these two @entity1 . All five @entity1 were alive at last follow-up, two with @entity3 ; but follow-up for this study is limited. CONCLUSIONS: A @entity2483 is an additional feature of the macrofollicular variant of @entity3557 that may aid in diagnosis and does not appear to have an adverse effect on the excellent prognosis of @entity1 with these @entity5 .

title: Macrofollicular variant of @entity3557 with XXXX .

entities_list: @entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid carcinoma']

entities_list: @entity3120 :: ('MESH:D009383', 'Disease') :: ['extrathyroidal and blood vessel invasion']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity2483 :: ('MESH:C566443', 'Disease') :: ['minor insular component']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinomas']

answer: @entity2483 :: (MESH:C566443,Disease) :: ['minor insular component']


abstract: PURPOSE: @entity130 dogma dictates that the physiologic response to injury is blunted by beta-blockers and other cardiac medications. We sought to determine how the @entity130 cardiac medication profile influences admission physiology and post-injury outcomes. MATERIALS AND METHODS: @entity130 @entity1 older than 45 evaluated at our center were retrospectively studied. Pre-injury medication profiles were evaluated for angiotensin-converting enzyme inhibitors / angiotensin receptor blockers (ACE-I/ARB), beta-blockers, @entity460 channel blockers, @entity2643 , or a combination of the above mentioned agents. Multivariable logistic regression or linear regression analyses were used to identify relationships between @entity130 medications, vital signs on presentation, @entity1317 , length of hospital stay, and mortality. RESULTS: Records of 645 @entity1 were reviewed (mean age 62.9 years, Injury Severity Score >10, 23%). Our analysis demonstrated no effect on @entity551 from beta-blocker, ACE-I/ARB, @entity460 channel blocker, and @entity2643 use. The triple therapy (combined beta-blocker, @entity460 channel blocker, and ACE-I/ARB) @entity1 group had significantly lower heart rate than the no cardiac medication group. No other groups were statistically different for heart rate, systolic, and diastolic blood pressure. CONCLUSIONS: Pre-injury use of cardiac medication lowered heart rate in the triple-agent group (beta-blocker, @entity460 channel blocker, and ACEi/ARB) when compared the no cardiac medication group. While most combinations of cardiac medications do not blunt the hyperdynamic response in @entity130 cases, @entity1 on combined beta-blocker, @entity460 channel blocker, and ACE-I/ARB therapy had higher mortality and more in-hospital complications despite only mild attenuation of the hyperdynamic response.

title: Pre-injury beta blocker use does not affect the hyperdynamic response in older XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['post-injury complications']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic and diastolic blood pressures']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['pre-injury', 'Trauma', 'trauma']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']


abstract: UNASSIGNED: Type 2 @entity6 is a very prevalent @entity102 . Among dietary factors for its prevention and treatment, interest has grown in satiating fibre (konjac glucomannan) and spirulina. Our previous studies suggest that glucomannan itself and/or in conjunction to spirulina displayed hypolipemic and antioxidant effects when incorporated to squid surimi as functional ingredients. The present study aims to determine whether @entity28128 - enriched or glucomannan plus spirulina-enriched squid-surimi improve plasma @entity413 and insulin levels in Zucker fa/fa @entity35 fed a high saturated fat diet. Twenty four growing @entity35 , divided into three groups, were given modified AIN-93M diets for seven weeks: 30% squid-surimi control diet (C), 30% glucomannan-enriched squid-surimi diet (G) and 30% glucomannan plus spirulina-enriched squid-surimi diet ( @entity1412 ). All @entity35 became @entity1602 and hyperinsulinemics, but G and @entity1412 diets induced significantly lower @entity413 levels (20%; p < 0.05) but did not modify insulinemia with respect to C diet. @entity1412 animals showed higher HOMA-D (p < 0.05) than C ones suggesting @entity101 . Plasma @entity10672 and adiponectin decreased in G and @entity1412 vs. C group (p < 0.05). Adipose adiponectin increased significantly in G and @entity1412 vs. C @entity35 (16-20 times, p < 0.01). @entity10672 in adipose tissue was higher in @entity1412 vs. G group (p < 0.05). In conclusion, both glucomannan-diets were able to reduce @entity4854 and increase adipose tissue adiponectin levels in fa/fa @entity35 , suggesting an anti- @entity1184 and insulin-sensitizing adipokine effect in this tissue. Spirulina inclusion @entity101 . Although results are promising, the utility of consuming glucomannan surimis as part of usual diets demands future studies.

title: GLUCOMANNAN AND GLUCOMANNAN PLUS SPIRULINA-ENRICHED SQUID-SURIMI ADDED TO HIGH SATURATED DIET AFFECT GLYCEMIA, PLASMA AND ADIPOSE @entity10672 AND ADIPONECTIN LEVELS IN GROWING FA/FA XXXX .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['increased insulin availability']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

entities_list: @entity28128 :: ('MESH:C022901', 'Chemical') :: ['glucomannan']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity1602 :: ('MESH:D006944', 'Disease') :: ['hyperglycemics']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity35 :: (10116,Species) :: ['RATS']


abstract: OBJECTIVE: To assess the efficacy and tolerability of @entity903 20mg daily, for the treatment of @entity308 and @entity308 associated with @entity148 . METHOD: An open, non-comparative study undertaken at three centers in three cities of Pakistan. A total of 112 in- or out- @entity1 , presenting with a major @entity308 were included in the study. @entity308 was diagnosed according to DSM IV criteria and a Hamilton Rating Scale for @entity308 (HAMD-D) score of >18 on the first 17 items of the HAM-D-21. After a placebo washout period of 7 days, @entity1 were given a 20-mg fixed dose of @entity903 daily in the morning for a period of 6 weeks. After baseline, regular assessments were made at 1, 2, 4 and 6 weeks. Efficacy measures included the HAMD-D, the Clinical Anxiety Scale, The Clinical Global Impression Severity of Illness Scale (CGI-S), and the Clinical Global Impression Improvement Scale (CGI-I). Tolerability was assessed by any adverse event. The primary therapeutic outcome measures were @entity1 who achieved a 50% or greater reduction in HAMD-D score at the end of the treatment or achieved a reduction in final HAMD-D score of < or = 10 points. The final scores of 1 or 2 for CGI-S and CGI-I were considered as full clinical response. RESULTS: Of 112 cases evaluated, 57 were males and 55 females whose ages ranged from 18 to 65 years. There was a clear and statistically significant efficacy of @entity903 on all the major outcome variables. A total of 88% @entity1 achieved a reduction in the final HAMD-D score at the end of treatment. The total HAM-D score reduced to 10 or less in 73% @entity1 at 6 weeks and by this week 76% and 92% @entity1 achieved a score of 1 or 2 for CGI-S and CGI-I, respectively. The mean Clinical Anxiety Scale score reduced from 12.6 at the baseline to 4.4 at the end of treatment. Safety data was evaluated in all 112 @entity1 and @entity903 was well tolerated. Adverse events were experienced by 10% of @entity1 of whom 4% were dropped from the study. @entity390 was the commonest adverse event reported. CONCLUSION: The study shows that @entity903 is an effective, well-tolerated, and safe drug for the treatment of @entity308 .

title: Efficacy and tolerability of @entity903 20 mg daily in the treatment of @entity308 and XXXX associated @entity148 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression', 'depressive episode']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: BACKGROUND AND OBJECTIVES: One of the most cellular source used for cartilage tissue engineering are mesenchymal stem cells (MSCs). In present study, @entity1 MSCs were used as cellular source. Since scaffold plays an important role in tissue engineering the aim of this study is to assess fibrin scaffold ability in chondrogenic differentiation of adipose-derived mesenchymal stem cells (ADMSCs). METHODS: ADMSCs were isolated and cultured in DMEM medium supplemented with 10% @entity4434 . Also ADMSCs expanded and characterised by flow cytometry. ADMSCs expressed @entity1759 , @entity5399 , CD105 but not @entity2280 . After trypsinization, cells were entered within the fibrin scaffold. Then, chondrogenic medium was added to the scaffold. Seven days after cell culture, cell viability and proliferation were assessed by @entity98 test. Finally, 14 days after the ending of chondrogenic differentiation, analysis of chondrogenic genes expression was evaluated by RT-PCR and Real time PCR. Also, formation and development of chondrocyte cells was analysed by histological and immunohistochemistry evaluations. RESULTS: Viability and proliferation as well as chondrogenic genes expression within fibrin scaffold increased significantly compared with control group (cells free scaffold). Also, histological and immunohistochemistry evaluation showed that chondrocyte cells and collagen type II are formed on fibrin scaffold. CONCLUSIONS: Fibrin is a suitable scaffold for chondrogenic differentiation of ADMSCs.

title: Fibrin Scaffolds Designing in order to XXXX Adipose-derived Mesenchymal Stem Cells Differentiation to Chondrocytes in the Presence of TGF-b3.

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: OBJECTIVE: To study the influence of adjustment of balance of @entity1198 /Th2 by external cytokines on proliferation of @entity11 cells. METHODS: The gene expressions of @entity1198 /Th2 type cytokines in C6, 9L, U251 and SHG44 @entity11 cells were detected by semiquantitative reverse transcription polymerase chain reaction (RT-PCR). After the cells were induced with @entity379 + @entity3646 McAb and @entity3646 + @entity379 McAb respectively, we isolated the total RNA to proceed RT-PCR again. The evaluation of cell proliferation was proceeded by @entity98 assay method. RESULTS: There was obviously predominant expression of Th2 type cytokines in @entity11 cell lines (P < 0.01). The expression intensity of @entity379 was improved in @entity379 + @entity3646 McAb groups and Th2 type cytokines were enhanced in @entity3646 + @entity379 McAb groups. @entity379 and @entity3646 McAb could cause the switch from Th2 to @entity1198 , and could remarkably inhibit the proliferation of @entity11 cells in a dose-dependent way (P < 0.01). On the other hand, @entity3646 and @entity379 McAb could strengthen the switch of Th2, and might stimulate the @entity11 cell growth, also in a dose-dependent way (P < 0.01). CONCLUSIONS: There is a Th2 preponderance in @entity11 cells. @entity379 and @entity3646 McAb could regulate the switch from Th2 to Th0 or @entity1198 , and inhibit the proliferation of @entity11 cells.

title: [Influence of adjustment of balance of XXXX /Th2 type cytokines on proliferation of @entity11 cells].

answer: @entity1198 :: (51497,Gene) :: ['Th1']


abstract: BACKGROUND: Few targeted therapies (TTs) are registered for @entity242 treatment despite numerous phase II studies and yet there are potential treatment options for @entity1 after standard treatment escape. The @entity242 Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of @entity1 treated with off-label TTs. METHODS: Every consecutive @entity242 - @entity1 receiving an off-label TT outside a clinical trial was included. The objective was to describe this @entity1 efficacy and safety data in routine practice. RESULTS: From October 2008 to October 2011, 249 @entity1 in 24 centers received 278 treatment lines with TTs. Twenty-five histological subtypes were included: most frequent were @entity1822 (n = 48, receiving sorafenib in 63%, and sunitinib in 27%), @entity677 (n = 39, receiving sorafenib in 79%), and @entity5426 (n =18, receiving sorafenib in 78%). The overall response rate to TTs was 15% (95% CI [10,6-20,2]), the disease control rate at 2  months was 59%. The median progression-free survival was 4,1  months (IC 95% [3,2-4,8]). Three complete responses were observed. No @entity137 occurred, grade 3 and 4 @entity137 were reported in 74 (27%) and 14 @entity1 (5%) respectively. CONCLUSION: Off-label TTs can be used for @entity242 @entity1 in routine practice with an acceptable @entity137 profile and efficacy similar to that reported in non-randomized clinical trials.

title: The off-label use of targeted therapies in XXXX : the OUTC'S program.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxic death', 'toxicities']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'French Sarcoma']

entities_list: @entity5426 :: ('MESH:D006394', 'Disease') :: ['angiosarcoma']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma']

answer: @entity242 :: (MESH:D012509,Disease) :: ['sarcomas']


abstract: Survivors of @entity385 are at significant risk for recurrent @entity64 . Appropriate therapy for @entity64 prevention is needed given the significant morbidity and mortality associated with @entity64 , the high financial costs, and the @entity16 associated with treatment failure. A treatment strategy based on assessed risk represents an appropriate use of medical resources and results in improved outcomes. This approach requires evaluation of major risk factors, the most serious of which is a history of @entity385 or transient @entity63 attack. The annual risk for recurrent @entity64 is 6% during the first 5 years after an initial @entity64 . Non-modifiable risk factors include age, race, ethnicity, gender, family history, and geography. The most important modifiable risk factor is @entity101 . @entity6 , @entity407 , @entity4346 , @entity955 , and lifestyle factors such as smoking, @entity988 , and @entity28 contribute to @entity64 risk. Antihypertensive, lipid-lowering, and antiplatelet therapies have been successful in reducing the incidence of @entity64 . Clinical trials validate the benefits of statin therapy in reducing the risk for @entity64 . Studies of antiplatelet agents, including @entity117 , @entity1397 , and @entity117 combined with extended-release @entity4341 , have evaluated the risk reduction in recurrent @entity64 and have been concerned particularly with the risk for @entity548 . Therapy for @entity64 prevention based on risk stratification can identify @entity1 who are appropriate targets for aggressive intervention.

title: Secondary prevention of XXXX : evolution from a stepwise to a risk stratification approach to care.

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['secondary stroke', 'stroke']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes mellitus']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity988 :: ('MESH:D000437', 'Disease') :: ['alcohol abuse']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic disability']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity4341 :: ('MESH:D004176', 'Chemical') :: ['dipyridamole']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['left ventricular hypertrophy']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']


abstract: Atrophy in a denervated muscle results from the disuse caused by paralysis of the muscle, and from the loss of special nerve-derived trophic substances. Crude preparations of protein from @entity35 or @entity742 sciatic nerves have been shown to prevent the nondisuse @entity194 of the @entity35 's extensor digitorum longus muscle when injected into the denervated muscle daily for 1 week. Aqueous extracts of @entity742 sciatic nerves were fractionated by gel-liquid chromatography. After each step of purification, the trophic activities of the various fractions were assayed in the @entity35 . Cross-sectional areas of type IIB muscle fibers in the denervated extensor digitorum longus were measured to determine which injected fraction contained the active principle. Affinity chromatography on concanavalin A-agarose revealed that the trophic substance was a glycoprotein. Further fractionation by gel filtration indicated that the active substance had a molecular weight in the range of 90,000 to 130,000. Ion-exchange chromatography on @entity8851 -cellulose yielded an active fraction containing substances with isoelectric points between 7.0 and 7.2, determined by @entity2975 gel isoelectric focusing. This active fraction was resolved into 15 bands on @entity3208 -gel electrophoresis. Two bands had apparent molecular weights of 91,300 and 127,400. The active factor was shown thus to be a glycoprotein, molecular weight approximately 100,000, isoelectric point approximately 7.0. It may be one of two protein bands that are similar to it in molecular weight.

title: Partial purification from mammalian peripheral nerve of a trophic factor that ameliorates XXXX of denervated muscle.

entities_list: @entity3208 :: ('MESH:D012967', 'Chemical') :: ['sodium dodecyl sulfate']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

answer: @entity194 :: (MESH:D001284,Disease) :: ['atrophy']


abstract: The role of diet, acculturation, and physical activity on systolic and diastolic blood pressure was examined among 1,420 Mexican American, 388 Cuban American, and 542 Puerto Rican @entity1 who responded to the Hispanic Health and Nutrition Examination Survey collected in 1982-4. Dietary intake measures included @entity1372 , @entity972 , @entity460 , @entity1760 , fiber, @entity1068 , and total kilocalories as estimated from 24-hour recall data. Serum @entity1372 / @entity972 ratio was included as a measure of metabolic function. Acculturation was measured using language preference, speaking, reading and writing. Physical activity included recreational and non-recreational activities. Other correlates included age, education, and body composition. Final models indicated that age and body composition were significantly associated with blood pressure across all three Hispanic subgroups. Among Mexican-American @entity1 , acculturation had an impact on both systolic and diastolic blood pressure that was independent of diet, body composition, and physical activity. Furthermore, the dietary intake of specific nutrients such as @entity1372 and @entity972 did not appear to be as important as the way the individual metabolized those nutrients, as indicated by the serum @entity1372 / @entity972 ratio. The strong association of body mass index with both systolic and diastolic blood pressure among all three ethnic groups reinforces the need to maintain an appropriate body weight.

title: Blood pressure in Hispanic XXXX : the role of diet, acculturation, and physical activity.

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: The differentiation of extramedullary myelogenous @entity2800 ( @entity2800 ) from @entity706 can sometimes be difficult. In the current study, we explored the value of @entity2280 , @entity3335 and nonspecific esterase (Leder) stains in differentiating @entity706 . MATERIALS AND METHODS: Fifteen cases of phenotypically confirmed @entity2800 were stained for @entity2280 , @entity3335 and Leder stains. The same stains were performed in 16 @entity706 as controls. The @entity2800 cases were also immunostained for CD3 and @entity2225 to detect the incidence of aberrant T and B lymphocyte expression. RESULTS: @entity2280 was expressed in 7 of the 15 cases of @entity2800 (46%). @entity3335 was expressed in 10 of the 15 cases (66%), and Leder stain was positive in 9 cases (60%). All 15 cases had expression of at least one marker; 8 cases had expression of two markers and one case had expression of all 3 markers. None of the @entity706 showed expression of any of the three markers. Five cases (35%) of @entity2800 showed T cell antigen expression and 2 (14%) showed B cell antigen expression. CONCLUSION: Our findings suggest that in cases of @entity2800 , the use of the combination of @entity2280 , @entity3335 and Leder stains can help reach a definitive diagnosis, especially if @entity706 is difficult to exclude. Expression of B and T cell antigens in such lesions should not rule out the diagnosis of @entity2800 .

title: The value of XXXX , @entity3335 and chloroacetate esterase (Leder) stain in the diagnosis of granulocytic sarcoma.

entities_list: @entity3335 :: ('4353', 'Gene') :: ['Myeloperoxidase', 'myeloperoxidase']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'malignant lymphomas', 'GS from lymphomas', 'malignant lymphoma', 'lymphomas']

entities_list: @entity2800 :: ('MESH:D007951', 'Disease') :: ['GS', 'leukemia/granulocytic sarcoma']

answer: @entity2280 :: (947,Gene) :: ['CD34']


abstract: @entity3473 is a @entity600 of the craniovertebral junction in which the odontoid abnormally prolapses into the foramen magnum. It is also associated with @entity1645 , @entity1644 , and @entity1276 . @entity1 require surgical treatment to prevent progression of @entity16 , but assessment of anterior or posterior decompression can be difficult owing to bone instability and ambiguous compression of neural structures. Here, we describe a case of @entity3473 in a young adult. He presented with @entity16 , including @entity1644 , 3 months after a traffic trauma that might have led to instability of the bony structures. Since it was unclear whether the instability of the bony structures contributed to the clinical deterioration, the @entity1 was first treated using halo-vest fixation. Significant improvements were observed in both @entity16 and magnetic resonance images. These results justified the invasive fixation and the @entity1 was treated further with an occipito-cervical fusion ; good results were achieved in this case. Owing to the invasiveness of the procedure, occipito-cervical fixation should only be adopted following strict indication criteria. Halo-vest fixation was effective in treating the instability of the bony structures and as a trial treatment for permanent fixation.

title: [Efficacy of halo-vest fixation in the assessment and prediction of the effectiveness of permanent fixation in a XXXX with @entity3473 with ambiguous vertebral instability].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patient']

entities_list: @entity1644 :: ('MESH:D013595', 'Disease') :: ['syringomyelia']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity1645 :: ('MESH:D001139', 'Disease') :: ['Chiari malformation']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological symptoms']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['developmental anomaly']

entities_list: @entity3473 :: ('MESH:D007443', 'Disease') :: ['Basilar invagination', 'basilar invagination']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: BACKGROUND: Symptoms and survival of @entity1 with @entity4303 have improved, but development of @entity299 ( @entity299 ) continues to decrease survival. OBJECTIVES: This study aimed to analyze @entity1 outcomes after valve surgery for @entity299 during a 27-year period at 1  institution to determine early and late outcomes and opportunities for improved @entity1 care. METHODS: We retrospectively studied the short-term and long-term outcomes of all consecutive @entity1 with @entity299 who underwent valve replacement at our institution between 1985 and  2012. RESULTS: The records of 195 @entity1 with @entity299 were analyzed. Pre-operative New York Heart Association class was III  or IV in 125 of 178 @entity1 (70%). All had tricuspid valve replacement (159 bioprostheses, 36 mechanical), and 157  underwent a @entity338 . Other concomitant operations included mitral valve procedure (11%), aortic valve procedure (9%), @entity4616 or @entity118 closure (23%), cardiac metastasectomies or biopsy (4%), and simultaneous coronary artery bypass (11%). There were 20 perioperative @entity204 (10%); after 2000, perioperative mortality was 6%. Survival rates (95% confidence intervals) at 1, 5, and 10 years were 69% (63% to 76%), 35%  (28% to 43%), and 24% (18% to 32%), respectively. Overall mortality was associated with older age, cytotoxic chemotherapy, and @entity286 use; 75% of survivors had symptomatic improvement at follow-up. Presymptomatic valve operation was not associated with late survival benefit. CONCLUSIONS: Operative mortality associated with valve replacement surgery for @entity299 has decreased. Symptomatic and survival benefit is noted in most @entity1 when @entity299 is managed by an experienced multidisciplinary team.

title: Early and Late Outcomes of Surgical Treatment in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['pulmonary valve operation']

entities_list: @entity4303 :: ('MESH:D002276', 'Disease') :: ['carcinoid syndrome']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['carcinoid heart disease', 'CaHD']

entities_list: @entity118 :: ('MESH:D006344', 'Disease') :: ['atrial septal defect']

entities_list: @entity4616 :: ('MESH:D054092', 'Disease') :: ['patent foramen ovale']

answer: @entity299 :: (MESH:D006331,Disease) :: ['Carcinoid Heart Disease']


abstract: UNASSIGNED: @entity308 is common, and imposes a high burden in terms of cost, morbidity, and suffering. Most @entity1 with @entity308 are treated in general medicine using antidepressant medication. Outcomes are poor due to failure points across the care system, including @entity1 non-adherence, failure of physicians to optimize the treatment regimens, and lack of @entity1 -physician communication. This study reports on the 4-week pilot deployment of MedLink, a mobile intervention aimed at systemically addressing each of these failure points. A mobile app provides the @entity1 with information and collects data on symptoms and side-effects. A cellularly enabled pill bottle monitors medication adherence. Data from these are provided to the physician and @entity1 to foster communication and medication adjustments. Usability evaluation was generally favorable. Medication adherence rates in this first deployment were high with no @entity1 discontinuing, and 84% of doses taken. Depressive symptom severity was significantly reduced. This study supports the use of a comprehensive, systemic approach to mHealth solutions to enhance processes of care for @entity308 by general medicine physicians.

title: MedLink: A Mobile Intervention to Address Failure Points in the Treatment of XXXX in General Medicine.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'Major depression']

answer: @entity308 :: (MESH:D003866,Disease) :: ['Depression']


abstract: UNASSIGNED: @entity34389 aerobically respires with several terminal oxidases. The @entity9151 oxidase (Cyo) encoded by cyoABCD is needed for efficient adaptation to low @entity26 conditions, and cyo transcription is up-regulated at low @entity26 . This study sought to determine how transcription of the cyo operon is regulated. The 5' sequence upstream of cyo was analyzed in silico and revealed putative binding sites for ActR of the ActSR two-component regulatory system. The expression of cyo was decreased in an actSR mutant regardless of the @entity26 condition. Because ActSR is known to be important for growth at low pH in another rhizobial species, the effect of growth-medium pH on cyo expression was tested. As the pH of the media was incrementally decreased, cyo expression gradually increased in the wild type, eventually reaching approximately 10-fold higher levels at low pH (4.8) compared to neutral pH (7.0) conditions. This up-regulation of cyo under decreasing pH conditions was eliminated in the actSR mutant. Both the actSR and cyo mutants had severe growth defects at low pH (4.8). Lastly, the actSR and cyo mutants had severe growth defects when grown in media treated with an @entity68 chelator. In this condition, cyo was up-regulated in the wild type whereas cyo was not induced in the actSR mutant. Altogether, the results indicate cyo expression is largely dependent on the ActSR 2-component system. This study also demonstrates additional physiological roles for Cyo in @entity34388 , in which it is the preferred oxidase for growth in acidic and low @entity68 conditions.

title: The XXXX oxidase encoded by cyoABCD in @entity34388 is regulated by ActSR and is crucial for growth at low pH or low @entity68 conditions.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity34389 :: ('29449', 'Species') :: ['Rhizobium etli']

answer: @entity9151 :: (CHEBI:17594,Chemical) :: ['quinol']


abstract: OBJECTIVE: Acids, such as those used in adhesive dentistry, have been shown to solubilize bioactive molecules from dentin. These @entity2483 ( @entity2483 ) may promote cell proliferation and differentiation, and ultimately contribute to dentin regeneration. The objective of this study was to evaluate the potential for varying concentrations of @entity2483 extracted from @entity1 dentin by @entity8718 of a range of pHs to stimulate proliferation and mineralization of two different cultured pulp cell populations. METHODS: @entity2483 were solubilized from powdered @entity1 dentin (7 days - 4  C) by @entity8718 of pH 1, 3, and 5 and also, @entity1098 . Extracts were dialyzed for 7 days against distilled water and lyophilized. Undifferentiated @entity19 dental pulp cells (OD-21) and cells of the odontoblast-like cell line (MDPC-23) were seeded in six-well plates (1*10(5)) and cultured for 24h in DMEM (Dulbecco's modified Eagle's medium) containing 10% (v/v) @entity2241 ( @entity2241 ). The cells were washed with serum-free medium and then treated with different concentrations of @entity2483 (0.01, 0.1, 1.0 and 10.0 g/ml) daily in serum free medium for 7 days. After 3, 5 (MDPC-23 only), and 7 days of treatment, cell proliferation was measured using 10vol% @entity30367 solution, which was added to each well for 1h. Cell numbers were first measured by cell counting ( @entity3460 ; n=5) and Alamar blue fluorescence to validate the assay, which was then used for the subsequent assessments of proliferation. Mineralization was assessed by @entity6033 assay after 12 days exposure to @entity2483 (n=5). Controls were media-only (DMEM) and @entity619 ( @entity9170 ; positive control). Results were analysed by ANOVA/Tukey's (p <=0.05). RESULTS: There was a linear correlation between cell counts and Alamar blue fluorescence (R(2)>0.96 for both cell types) , verifying the validity of the Alamar blue assay for these cell types. In general, there was a dose-dependent trend for enhanced cell proliferation with higher concentration of @entity2483 for both cell lines, especially at 10.0 g/ml. @entity9170 exposure resulted in significantly higher mineralization, but did not affect cell proliferation. @entity2483 exposure demonstrated significantly greater mineralization than media-only control for 10 g/ml for all extracts, and at lower concentrations for @entity1098 and pH 5 extracts. SIGNIFICANCE: @entity1 @entity2483 solubilized by acids at pH levels found in commercial dentin adhesives enhanced cell proliferation and mineralization of @entity19 and @entity35 undifferentiated dental pulp cells when presented in adequate concentration.

title: Dentin matrix components extracted with XXXX enhance cell proliferation and mineralization.

entities_list: @entity8718 :: ('MESH:C030242', 'Chemical') :: ['phosphoric acid']

entities_list: @entity30367 :: ('MESH:C005843', 'Chemical') :: ['Alamar blue']

entities_list: @entity6033 :: ('MESH:C004468', 'Chemical') :: ['Alizarin Red S']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity3460 :: ('MESH:D014343', 'Chemical') :: ['Trypan blue']

entities_list: @entity2483 :: ('MESH:C566443', 'Disease') :: ['DMC', 'dentin matrix components']

entities_list: @entity2241 :: ('MESH:D005315', 'Disease') :: ['FBS', 'fetal bovine serum']

answer: @entity8718 :: (MESH:C030242,Chemical) :: ['phosphoric acid']


abstract: PURPOSE: In the United States, the prevalence of the use of alternative @entity286 products (ATPs) (e.g., hookahs, e-cigarettes, cigars/cigarillos) has increased sharply. As future health care providers, medical students will play a critical role in health promotion and disease prevention. This study investigated medical students' use, knowledge, and beliefs about cigarettes and @entity855 s. METHOD: In 2014, the authors surveyed all students enrolled at one medical school in New York City. The survey included questions about personal use of @entity286 products, perceptions about the harms of ATPs and their role in disease causation, education about ATPs, and cessation training and practices related to @entity855 s and cigarettes. The authors compared results across medical school classes. RESULTS: Of 720 students, 431 (59.9%) completed the survey. Of those, 64 (14.7%) were current users of @entity286 or smoking products, including cigarettes (17; 3.9%), @entity855 s (21; 4.8%), or marijuana (39; 8.9%). Many believed that @entity855 s contributed less than cigarettes to various diseases. Respondents received less cessation training regarding ATPs than cigarettes (P < .0001). They felt less confident providing @entity855 cessation counseling than cigarette cessation counseling (P < .0001) and were less likely to report counseling @entity1 on @entity855 cessation than cigarette cessation (46 [10.7%] versus 280 [64.8%], P < .0001). CONCLUSIONS: A concerning percentage of surveyed medical students use @entity286 products, including @entity855 s, and lack the knowledge, education, and cessation counseling skills to provide accurate information about them to @entity1 . @entity855 education should be added to medical school curricula to address this gap.

title: A Study of the Use, Knowledge, and Beliefs About Cigarettes and Alternative XXXX Products Among Students at One U.S. Medical School.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity286 :: (4097,Species) :: ['Tobacco']


abstract: STUDY DESIGN: In vitro experimental studyOBJECTIVE.: To investigate the effect of @entity258 ( @entity258 ) on the extracellular matrix (ECM) synthesis of degenerative @entity1 nucleus pulposus cells and explore the molecular mechanism. SUMMARY OF BACKGROUND DATA: @entity258 has been used successfully for bone @entity174 healing and been proved to be effective in stimulating ECM metabolism in animal intervertebral disc cells. However, whether @entity258 also exerts an anabolic effect on degenerative @entity1 nucleus pulposus cells and the possible molecular mechanism is still unclear. METHODS: The degenerative @entity1 nucleus pulposus cells were cultured in @entity460 alginate beads. In the @entity258 group, cells were exposed to an average temporal intensity of 30mW/cm2 and a frequency of 1.5MHz of @entity258 20 minutes daily for 1 week. The control group was cultured in the same way but without @entity258 stimulation. The @entity2306 group was stimulated by @entity258 and treated with @entity2306 simultaneously. The expression of aggrecan, collagen-II, @entity1935 , tissue inhibitor of metalloproteinase-,1and matrix metalloproteinase-3 were evaluated by Enzyme-Linked Immunosorbent Assay, Western blot or RT-PCR. Expression of signaling proteins involved in @entity3818 / @entity10412 / @entity584 pathway was studied by Western blot analysis. RESULTS: @entity258 significantly upregulated expression of aggrecan, collagen-II, @entity1935 , and tissue inhibitor of metalloproteinase-1 compared with control group, but inhibited secretion of matrix metalloproteinase-3. The study further demonstrated that the upregulation of aggrecan, collagen-II, and @entity1935 was related to the activation of @entity3818 ( @entity3818 )// @entity10412 / @entity584 pathway caused by @entity258 . Moreover, inhibition of @entity10412 / @entity584 significantly suppressed the special biological effect activated by @entity258 . CONCLUSION: @entity258 promotes the ECM synthesis of degenerative @entity1 nucleus pulposus cells through activation of @entity3818 / @entity10412 / @entity584 pathway. LEVEL OF EVIDENCE: N/A.

title: Low Intensity Pulsed Ultrasound Promotes the Extracellular Matrix Synthesis of Degenerative @entity1 Nucleus Pulposus Cells Through @entity3818 / XXXX / @entity584 Pathway.

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3818 :: ('5747', 'Gene') :: ['FAK', 'focal adhesion kinase']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['LIPUS', 'low-intensity pulsed ultrasound']

answer: @entity10412 :: (5293,Gene) :: ['PI3K']


abstract: AIM: Morphologic risk factors for developing @entity454 ( @entity454 ) due to @entity8 may be difficult to identify in populations where the course is benign in the vast majority. Ours is a high-risk population. METHODS: Protocols of 67 biopsies from native kidneys of kidney transplant @entity1 with @entity8 were reevaluated with respect to the prevalence of certain structural findings. Time points for onset of symptoms, biopsy procedure, and @entity454 were recorded. RESULTS: Features seen with more than expected frequency were: extracapillary proliferation in 49%, cellular infiltrates in the interstitium in 89%, marked @entity194 in 54%, and IgA deposits in the peripheral capillary loops in 71%. With extracapillary proliferation the remaining time to @entity454 was 3.5 +/- 3.2 versus 7.0 +/- 4.2 years without (p < 0.0004). With marked @entity194 the remaining time was 3.5 +/- 2.7 and 8.2 +/- 4.2 years without (p = 0.0002). Cellular infiltrates in the interstitium also signified shorter progression (p = 0.009). Except for the presence of IgA in the periphery, no finding by immune fluorescence was more frequent than expected or correlated with progression. CONCLUSION: Extracapillary proliferation, interstitial cellular infiltrates, marked @entity194 , and IgA deposits in the peripheral capillary loops indicate risk of progressive @entity177 in @entity8 , but other findings by immune fluorescence do not.

title: Morphologic high-risk factors in XXXX .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['IgA nephropathy']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity194 :: ('MESH:D001284', 'Disease') :: ['tubular atrophy']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD', 'end-stage renal failure']

answer: @entity8 :: (MESH:D007674,Disease) :: ['IgA nephropathy']


abstract: Cetuxiamb, a monoclonal antibody against @entity470 ( @entity470 ), has been used in combination with chemotherapy for @entity1 with metastatic @entity14 (mCRC). However, the efficacy of combined therapies of cetuximab and different chemotherapy regimens remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and @entity137 of adding cetuximab to @entity901 -based or @entity2600 -based chemotherapeutic regimens for the treatment of @entity1 with mCRC with wild-type/mutated @entity984 @entity5 . Randomized controlled trials (RCTs), published in Pubmed and Embase were systematically reviewed to assess the survival benefits and @entity137 profile mCRC @entity1 treated with cetuximab plus chemotherapy. Outcomes included @entity1349 ( @entity1349 ), progression-free survival (PFS), overall response rate (ORR), and @entity137 . Results were expressed as the hazard ratio (HR) with 95  % confidence intervals (CI). Pooled estimates were generated by using a fixed-effects model or a randomized-effects model, depending on the heterogeneity among studies. A total of 12 trials involving 6,297 @entity1 met the inclusion criteria and were included in this meta-analysis. All @entity1 were administered @entity901 -based or @entity2600 -based chemotherapy with or without cetuximab. Pooled results showed that the addition of cetuximab did not significantly improve the @entity1349 (HR   =   0.99, 95  % CI   =   0.89-1.09; Z   =   0.28, P   =   0.78) or PFS (HR   =   0.94, 95  % CI   =   0.81-1.10; Z   =   0.76, P   =   0.49), but did improve ORR (RR   =   1.34, 95  % CI   =   1.08-1.65; Z   =   2.72, P   =   0.00), when compared with chemotherapy alone. Subgroup analysis showed the highest PFS benefit in @entity1 with wild-type @entity984 @entity5 (HR   =   0.80, 95  % CI   =   0.65-0.99; Z   =   2.1, P   =   0.04) or wild-type @entity984 / @entity817 @entity5 (HR   =   0.64, 95  % CI   =   0.52-0.79; Z   =   4.15, P   =   0.00). When combined with cetuximab, @entity2600 -based chemotherapy was significantly associated with prolonged PFS (HR   =   0.79, 95  % CI   =   0.66-0.96; Z   =   2.36, P   =   0.02) for all @entity1 with differing gene-status. The incidence of grade 3/4 adverse events, including @entity137 , @entity294 , @entity101 , @entity448 , and @entity33 / @entity3136 , was slightly higher in the combined therapy group than in the chemotherapy-only group. Based on the current evidence, the addition of cetuximab to chemotherapy significantly improves the PFS in @entity1 with wild-type @entity984 or wild-type @entity984 / @entity817 @entity5 as well as the ORR in all @entity1 . In addition, @entity2600 -based combination therapy showed a beneficial effect on the PFS in all @entity1 . These findings confirm the use of cetuximab in combination with chemotherapy for the treatment of @entity1 with mCRC with wild-type @entity984 @entity5 . Further multi-center RCTs are needed to indentify these findings.

title: Efficacy and @entity137 of adding cetuximab to chemotherapy in the treatment of metastatic XXXX : a meta-analysis from 12 randomized controlled trials.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'skin toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: BACKGROUND AND PURPOSE: Positron emission tomography (PET) with @entity9241 ( @entity9241 ) provides a non-invasive assessment of @entity519 . The aim of this study is to assess the feasibility of a dose escalation with volumetric modulated arc therapy (VMAT) guided by @entity9241 -PET for @entity135 ( @entity135 ). @entity1 AND METHODS: Ten @entity1 with inoperable stages III-IV @entity135 underwent @entity9241 -PET before radiotherapy. @entity519 target volumes (HTV) were segmented automatically by using the fuzzy locally adaptive Bayesian method. Retrospectively, two VMAT plans were generated delivering 70  Gy to the gross @entity5 volume (GTV) defined on computed tomography simulation or 79.8  Gy to the HTV. A dosimetric comparison was performed, based on calculations of @entity5 ( @entity5 ), normal tissue complication probability (NTCP) for the parotid glands and uncomplicated @entity5 (UTCP). RESULTS: The mean @entity519 fraction, defined as the ratio between the HTV and the GTV, was 0.18. The mean average dose for both parotids was 22.7  Gy and 25.5  Gy without and with dose escalation respectively. FMISO-guided dose escalation led to a mean increase of @entity5 , NTCP for both parotids and UTCP by 18.1, 4.6 and 8   % respectively. CONCLUSION: A dose escalation up to 79.8  Gy guided by @entity9241 -PET with VMAT seems feasible with improvement of @entity5 and without excessive increase of NTCP for parotids.

title: @entity519 imaging with XXXX -PET for guided dose escalation with intensity-modulated radiotherapy in @entity135 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['HNC', 'head-and-neck cancers']

entities_list: @entity9241 :: ('MESH:C031843', 'Chemical') :: ['[(18)F]-FMISO', '[(18)F]-fluoromisonidazole']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour control probability', 'TCP', 'tumour']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxic', 'hypoxic', 'hypoxia']

answer: @entity9241 :: (MESH:C031843,Chemical) :: ['[18F]-FMISO']


abstract: PURPOSE: Nutrition plays an important role in brain structure and function, and the effects of diet may even be greater in those at greater risk of @entity73 , such as individuals with @entity5 -related @entity73 . However, the relation of dietary components to cognitive function in @entity5 survivors is unknown. The objective of this study was to determine whether @entity0 survivors (BCS) evidenced impairments in interference control, a component of cognitive control, compared to age-matched @entity1 with no prior history of @entity5 , and to examine the moderating role of diet on cognitive function. METHODS: In this cross-sectional study, a modified flanker task was used to assess interference control in BCS (n  =  31) and age-matched @entity1 with no prior history of @entity5 (n  =  30). Diet was assessed with 3-day food records. Differences between BCS and age-matched controls were assessed using linear mixed models, and multilevel regression analyses were conducted to assess the moderating role of  diet on cognitive performance. RESULTS: Cognitive performance was not different between groups. Fruit intake and vegetable intake were significantly associated with better performance on the incompatible condition of the flanker task (i.e., shorter reaction time and increased accuracy), independent of disease status. The association between dietary components and cognition was stronger for the incompatible @entity558 , suggesting that fruit and vegetables may be important for the up-regulation of cognitive control when faced with higher cognitive demands. CONCLUSIONS: There was no difference in performance on an interference control task between BCS and age-matched controls. The data suggest that greater fruit intake and vegetable intake were positively associated with interference control in both BCS and age-matched controls.

title: Relationship between fruit and vegetable intake and interference control in XXXX survivors.

entities_list: @entity558 :: ('MESH:C536528', 'Disease') :: ['incongruent condition']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'cognitive decline']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: A group of 29 @entity1 with simultaneous @entity301 and @entity1028 were treated following two protocols: Group I, 16 @entity1 had coronary bypass surgery and then @entity1028 repair at a later date. This required two hospitalizations and two separate surgeries. Group II, 11 @entity1 , underwent coronary bypass surgery and repair of @entity1028 ( @entity1028 ) in one sitting. Group III, 2 @entity1 , had PTCA prior to @entity1028 repair. There were 3.1 bypass grafts implanted (Group I), vs 2.9 (Groups II) (ns). All @entity439 were infrarenal and 22 @entity1 had straight tube graft replacement (76%), and seven bifurcated grafts. Two @entity1 with @entity951 also had symptomatic @entity1028 . Period of hospitalization, morbidity, mortality, time of total recovery, hospital costs, and apprehension of @entity1 were analyzed. There was one death in Group I. In this group, the total recovery time was 4.8 months vs 2.4 months for Group II. Hospitalization time was 16.2 days in Group I vs 8.2 days in Group II. The hospital costs were significantly higher in Group I with an average of  58,950 vs  46,553 in Group II. No @entity204 occurred in Group II. It is recommended that if a @entity1 with severe @entity301 requiring surgery also presents with an @entity1028 of more than 5 cm, he/she should have both conditions operated on in one session rather than staggering the procedures. It saves time, cost, @entity148 , and is well tolerated.

title: One-Stage Coronary Bypass and XXXX Repair

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['abdominal aneurysms']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm', 'AAA']

answer: @entity1028 :: (MESH:D017544,Disease) :: ['Abdominal Aortic Aneurysm']


abstract: AIMS: To evaluate @entity86 after Greenlight    photovaporisation of the prostate ( @entity12468 ), through a dedicated questionnaire. METHODS: A retrospective study has been conducted between 2008 and 2014. The questionnaire had 5 sections about @entity158 while voiding, @entity811 , urgency, @entity322 and urinary stream, and was filled at one-month postoperative. The main outcome criterion was @entity158 while voiding. Descriptive statistical analyses were done to identify predictive factors for @entity158 while voiding. RESULTS: Out of 169 @entity1 , 22% had no @entity158 while voiding, 37% had moderate @entity158 , 30% acceptable @entity158 and 11% intense @entity158 . @entity1 with @entity158 were significantly older, (P=0.012), had more urgency (P=0.01) and more often @entity811 (P=0.0001). Only 7% of @entity1 had no symptoms of urgency, and urgency was painful or bothering in 57% of cases. @entity811 was frequent, with clots in 21% of cases. Ninety three percent felt improvement of urinary stream. CONCLUSIONS: Systematic evaluation of symptoms through a dedicated questionnaire one month after @entity12468 has shown that 41% of @entity1 felt @entity158 while voiding, 57% had urgency and 39% significant @entity811 . These results should encourage a more accurate @entity1 information and further studies to better understand postoperative healing after @entity12468 . LEVEL OF EVIDENCE: 5.

title: [Evaluation of XXXX after Greenlight    photovaporization of the prostate through a dedicated questionnaire].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative symptoms']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria', 'Hematuria']

answer: @entity86 :: (MESH:D019106,Disease) :: ['postoperative symptoms']


abstract: @entity195 ( @entity195 ) is the most prevalent @entity179 in @entity1 and is characterized by @entity528 , @entity3072 and @entity527 . The interaction between neurotrophins and their @entity24663 ( @entity24663 ) receptors is important for cellular differentiation and survival. Interestingly, marked reductions in neurotrophins and receptors have been reported in @entity195 . The cause of the decrease in these molecules remains unclear. However, the role of beta-amyloid ( @entity477 ) appears central in understanding the mechanisms controlling @entity2252 / @entity24663 expression. In this study we exposed SHSY5Y @entity521 cells to @entity477 or hydrogen peroxide and measured the expression of @entity12715 /truncated @entity12715 , and @entity2252 ( @entity2252 )/ @entity19563 at the protein and molecular level. We show that @entity477 or hydrogen peroxide (H(2)O(2)) induces oxidative stress and cell @entity137 . The exposure of cells to @entity477 results in an increased @entity12715 expression with a concurrent reduction in truncated @entity12715 levels. H(2)O(2) exposure decreased both @entity12715 and truncated @entity12715 levels at the cell surface. At the molecular level @entity12715 RNA increased in the presence of @entity477 and was unaffected by H(2)O(2). Similarly, @entity2252 and @entity19563 levels increased in the presence of @entity477 . Pre-treatment of cells with the anti-oxidant melatonin returns @entity24663 receptor expression, mRNA and @entity2252 / @entity19563 secretion to normal levels. These results are significant as they can help in the planning and implementation of @entity195 treatment strategies involving neurotrophins.

title: Beta-amyloid modulates @entity24663 B receptor expression in SHSY5Y XXXX cells: influence of the antioxidant melatonin.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['beta-amyloid deposition']

entities_list: @entity3072 :: ('MESH:C536599', 'Disease') :: ['neurofibrillary tangles']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disease']

entities_list: @entity2252 :: ('627', 'Gene') :: ['brain-derived neurotrophic factor', 'BDNF', 'neurotrophin']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

answer: @entity521 :: (MESH:D009447,Disease) :: ['neuroblastoma']


abstract: The dysfunction of homologous and/or heterologous gap junctional intercellular communication (GJIC) has been implicated in tumorigenesis of many kinds of cells. Here we have characterized GJIC and the expression of connexins in six @entity1 @entity2 cell lines and normal lung fibroblasts ( @entity15263 ). Compared with @entity15263 , all the @entity189 cells showed reduced or little homologous GJIC. They expressed remarkably reduced connexin(Cx)43 mRNA and variable levels of @entity28292 mRNA, but neither @entity495 nor @entity28292 protein could be detected. However, using a preloading assay, transfer of @entity5384 was observed between donor @entity15263 cells and first order neighboring recipient @entity5 cells (recipient cells in 1000-fold excess). Transfer from @entity5 to @entity15263 cells under the same conditions was not seen, although increasing the ratio of donor @entity5 cells to recipient @entity15263 cells and plating the cells at low density did reveal weak transfer from @entity5 cells to @entity15263 . Transfection of @entity495 into giant cell @entity189 PG cells increased homologous communication and eliminated the rectifying behavior of heterologous communication. This indicates that the apparent rectification of dye transfer between normal and @entity5 cells was a product of low rates of heterologous transfer linked to (i) rapid dilution of the dye to below detectable limits through a very well coupled cell population ( @entity5 to @entity15263 ) and (ii) concentration of dye in immediate neighbors in a poorly coupled cell population ( @entity15263 to @entity5 cells). These results suggest that the coupling levels may need to exceed a certain threshold to allow propagation of signals over a sufficient distance to affect behavior of a cell population. We propose that the relative rates of heterologous and homologous coupling of cell populations and the 'pool size' of shared metabolites in @entity5 cells and the surrounding normal tissue are likely to be very important in the regulation of their growth.

title: Effective asymmetry in gap junctional intercellular communication between populations of @entity1 normal lung fibroblasts and XXXX cells.

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung carcinoma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung carcinoma']


abstract: OBJECTIVE: @entity2172 ( @entity2172 ) is a common diagnosis in the pediatric population that is usually managed on an outpatient basis. A small proportion of @entity1 are admitted due to a @entity66 . The aim of this study was to investigate the demographics of those @entity1 and the resources utilized during their admissions. STUDY DESIGN: Retrospective review based on the 2009 Kids' Inpatient Database. SETTING: Nationwide administrative database. SUBJECTS AND METHODS: A review based on the 2009 Kids' Inpatient Database was conducted. Inclusion criteria were clinical modification codes for @entity2172 (ICD-9 code 382). Data recorded included @entity1 demographics, concurrent discharge diagnosis codes, length of stay, total charges, and frequency of procedures performed. RESULTS: There were 61,783 (92,548 nationally weighted) admissions with @entity2172 , which were analyzed. The average age (SD) for the @entity1 was 2.18 (3.49) years, and the average length of stay was 2.88 days. The majority (80.75%) of @entity1 did not have to undergo a procedure during admission, whereas a small proportion (5.4%) underwent a major operating room procedure. There were 21 deaths recorded (0.03%). A diagnosis of @entity2267 , @entity693 , @entity50 , or @entity932 was associated with significantly increased length of stay, incidence of procedures, and total cost of admission. CONCLUSIONS: Complicated pediatric @entity2172 remains of concern requiring prompt and thorough management. Major complications include @entity2267 and @entity693 , and unfortunately, fatalities still occur in @entity1 with @entity2172 . An understanding of resource utilization and socioeconomic implications can identify and drive opportunities for targeted quality improvement.

title: Complications of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity2172 :: ('MESH:D010033', 'Disease') :: ['Otitis media', 'OM']

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial abscess']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['complex disease course']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity2267 :: ('MESH:D008417', 'Disease') :: ['mastoiditis']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['venous sinus thrombosis']

answer: @entity2172 :: (MESH:D010033,Disease) :: ['Pediatric Otitis Media']


abstract: @entity11906 ( @entity17849 ) is a promising alternative to the phased-out fumigant @entity5495 ( @entity5496 ); however, there are concerns about its environmental fate following soil fumigation. Laboratory experiments were conducted to investigate the effect of various environmental factors on the rate of @entity17849 degradation in soil. The chemical was added to soil at 48.6 mg kg(-1) and incubated under different conditions. The @entity17849 degradation rate in soil was determined by extracting and measuring residual concentrations over a 15 d incubation period. In soil, @entity17849 degradation followed availability-adjusted first-order kinetics. At 20 degrees C @entity17849 had a calculated half-life of 32 d in a sandy loam containing 4.3 g kg(-1) of organic @entity505 . It degraded more rapidly as temperature increased, exhibiting a half-life of 23 d at 30 degrees C. Amendment with 10% @entity291 manure shortened the half-life to 4 d at 20 degrees C. In both unamended and manure-amended soils, the half-life of @entity17849 greatly increased as the organic matter (OM) was removed and it only slightly increased in soils that were sterilized, indicating predominance of chemical reactions in @entity17849 degradation. Soil texture, mineralogy, and moderate moisture content had little influence on @entity17849 degradation. The degradation slowed as the chemical application rate increased. The results suggest that environmental factors, especially soil temperature and organic amendments, should be considered in combination with the minimum effective @entity17849 application rate for achieving satisfactory pest-control efficacy, reducing atmospheric volatilization, and minimizing groundwater contamination.

title: Degradation of XXXX in soil: effects of environmental factors.

entities_list: @entity11906 :: ('MESH:C014055', 'Chemical') :: ['Methyl iodide']

entities_list: @entity5495 :: ('MESH:C005218', 'Chemical') :: ['methyl bromide']

answer: @entity11906 :: (MESH:C014055,Chemical) :: ['methyl iodide']


abstract: OBJECTIVE: To determine @entity560 status in @entity1 with @entity3570 ( @entity3570 ). METHODS: Charts of all @entity1 with @entity3570 at the Shriners Hospital for @entity1 in Houston, Texas, seen between July 2011 and June 2013 were retrospectively reviewed. Daily intake of milk, vitamins, amount of screen time, and time spent outdoors were recorded along with height, weight, body mass index, and serum @entity560 levels. RESULTS: A total of 38 @entity1 were identified. The mean level of @entity560 was 58.8 nmol/L (23.5 ng/dL); 30 (81%) had insufficient levels, 50 to 75 nmol/L (20 to 30 ng/mL), or deficient levels, <50 nmol/L (<20 ng/mL). African American and Hispanic descent correlated with decreased levels (P = 0.017). Daily @entity560 supplementation correlated with increased levels (P = 0.046). CONCLUSIONS: Most @entity1 with @entity3570 have suboptimal @entity560 levels. Despite living in a sunny climate and spending at least 15 minutes per day outdoors, @entity1 with @entity3570 have suboptimal @entity560 levels. Healthcare providers should consider the routine measurement of @entity560 levels and advise supplementation accordingly in this @entity1 population.

title: Low 25-Hydroxyvitamin D Levels in XXXX with @entity3570 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'patient']

entities_list: @entity3570 :: ('MESH:D016135', 'Disease') :: ['SB', 'spina bifida']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: BACKGROUND/RATIONALE: Adherence to cholinesterase inhibitor (ChEI) is associated with treatment effectiveness in the treatment of @entity195 ( @entity195 ). We investigated the clinical adherence to @entity8124 in Taiwan. METHODS: This was a retrospective study. @entity1 treated with @entity8124 were recruited from Kaohsiung Medical University Hospital and Kaohsiung Municipal Ta-Tung Hospital from February 2004 to April 2013. We analyzed their treatment duration in months. RESULTS: A total of 273 @entity1 were included in our analysis. Sixty-seven @entity1 withdrew from @entity8124 treatment with mean treatment duration of 28.0    25.9 months. Better initial scores on the Mini-Mental Status Examination (P = .007), Cognitive Abilities Screening Instrument (P = .003), and the Clinical Dementia Rating Scale (CDR) Sum of Boxes (P = .011) were positively associated with clinical adherence. The clinical adherent rate was higher in the CDR-0.5 group than in the @entity8897 .0 group with significant difference. CONCLUSION: Although there are some limitations in our study, these findings indicate that early intervention with ChEI in @entity1 with @entity195 should be emphasized and may lead to a better clinical adherence.

title: Clinical Compliance of XXXX in Treating @entity195 in Taiwan.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

answer: @entity8124 :: (MESH:C076946,Chemical) :: ['Donepezil']


abstract: INTRODUCTION: pregnancy and childbirth are the physiological processes, but have a significant impact on both the functions of particular organs, and the @entity1 's body as a whole, and often lead to the emersion of different symptoms, which significantly reduce the quality of life. These are the @entity790 ( @entity790 ) during pregnancy and after childbirth. Mental and physical sufferings of @entity1 stimulate obstetrician-gynecologists and urologists to the joint search for the causes of @entity790 in @entity1 , to the differentiated work out of individual methods of prevention, improving of diagnosis and treatment of this pathology. AIM: to study the risk factors, including the presence of extragenital pathology in @entity1 with @entity790 . MATERIALS AND METHODS: preliminary survey has been carried out, 51 @entity1 - @entity1 have been defined with complaints for @entity790 - the main group. The urogynecological questionnaire has been filled in, the diaries have been kept on urination, the results of functional tests have been evaluated as well as of ultrasonography of the lower urinary tract. The comparison group consisted of 50 @entity1 who gave birth without any signs of @entity790 . RESULTS: the results of conducted resrearch indicate the important role of extragenital pathology, in addition to the burdened obstetric and gynecological history as a risk factor for @entity790 during pregnancy and after childbirth. CONCLUSIONS: the high frequency of @entity66 , which are the visceral manifestations of the syndrome of undifferentiated connective tissue @entity1141 in @entity1 of the main group, indicates that a generalized defect of connective tissue is one of the reasons for the manifestation of the symptoms of @entity790 during pregnancy and after childbirth in @entity1 of reproductive age. The gained results must be taken into account when developing the methodology of forecasting the @entity790 in @entity1 during pregnancy and after childbirth.

title: Risk factors for XXXX during pregnancy and after childbirth.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'patients', 'patient']

entities_list: @entity790 :: ('MESH:D014564', 'Disease') :: ['urogenital disorders', 'MUD', 'manifestation of urogenital disorders']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['somatic diseases']

answer: @entity790 :: (MESH:D014564,Disease) :: ['urogenital disorders']